Lanthio Pharma

Lanthio Pharma

Developing and commercializing lanthipeptides as innovative drugs for treating medical conditions.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
investor

€0.0

round
investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round

€20.0m

Acquisition
Total Funding000k
More about Lanthio Pharma
Made with AI
Edit

Lanthio Pharma is a Dutch biopharmaceutical company focused on discovering and developing therapeutic peptides for severe diseases with high unmet medical need. The company operates in the biopharmaceutical market, primarily targeting oncology and critical care medicine. Utilizing proprietary lanthionine-constrained peptide technology, Lanthio Pharma creates peptides with superior target selectivity and stability. These peptides are designed to interact specifically with certain receptors, making them highly effective for therapeutic use. The company's business model revolves around research and development, clinical trials, and eventual commercialization of these therapeutic peptides. Revenue is generated through partnerships, licensing agreements, and government grants. Lanthio Pharma serves clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies.

Keywords: biopharmaceutical, therapeutic peptides, oncology, critical care, lanthionine-constrained, target selectivity, stability, clinical trials, healthcare, research.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo